Stork.ai is leveraging its strong foundations in reproductive medicine, big data, and artificial intelligence to create next-generation fertility products that ultimately help people have babies. It is commercializing a decision assessment tool comprised of patent-pending, AI-based software (“STORK”) that reliably assesses embryo (blastocyst) quality. STORK was developed using a proprietary, multi-focal embryo image dataset from Weill Cornell’s Center for Reproductive Medicine. STORK can also predict genetic defects such as aneuploidy, which involves an abnormal number of chromosomes in the embryo.
This device allows for damage free handling of sensitive devices and surfaces, and for applications that involve quick attach and release of surfaces. The total market opportunity for this company is approximately 36 billion. Conventional techniques to grab surfaces use a vacuum/suction strategy but these suffer an intrinsic limit of adhesion strength—1 atm (approximately 100 kPa) and are bulky. The switchable adhesion device is an electro-osmotic pump that uses individually-controlled oscillating water droplets to easily, carefully and quickly pick and place tiles in parallel.
Folic acid supplements are used for preventing severe birth defects by maintaining the DNA integrity in the developing embryo. This technology describes two downstream metabolites of folic acid, one of which is an effective replacement for folic acid as a prenatal supplement, more directly impacting nucleotide synthesis. The other is a oral therapy for cancer, which has demonstrated prevention of tumor development in mouse models.
Key nutrient deficiencies are more common than one may think and can lead to major health problems. However, determining vitamin levels can be costly, time-consuming, and confusing. VitaScan enables fast, accurate, and low-cost testing of an individual's vitamins and micronutrients. With VitaScan's portable system, the consumer can avoid hospital blood work and get the scan done at a physician's office, clinic, or even at home.
About half of treated cancer patients receive platinum-based drugs (eg. cisplatin, carboplatin) alone or in co-administration with other anticancer agents. Despite their efficacy, their use is limited by toxic side effects and inherent or acquired resistance to platinum-based drugs by tumor cells. To address this challenge, a Cornell team lead by Prof. Justin Wilson have developed rhenium-based chemotherapeutics for treatment of platinum-resistant cancers.
90% of cancer-related deaths occur due to metastasis. While effective therapies exist to treat primary tumors, treatments to slow/stop metastasis remain ineffective. While immuno-oncology is a new avenue for fighting these metastasized tumors, priming the immune cells has proven difficult. Here, the lab of Prof. King demonstrates a new method to functionalize immune cells. This technology can be applied to metastatic forms of prostate (1.1 million men diagnosed in 2012) and colorectal cancer (1.2 million cases diagnosed in 2015.)
Solutions for silent speech production lack innovation, cultural acceptability, and often involve invasive surgery. MyophonX is cutting-edge wearable technology for silent communication, with applications to stroke and laryngectomy patients as well as voice searching.
Exotanium is a startup created by two professors and one graduated Ph.D. student from the Department of Computer Science at Cornell University. Exotanium is developing a new cloud-native application container platform that improves performance, security, and cost for both public and private clouds. The technology is based on cutting-edge research and is patent-protected. Exotanium recently won a Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) and is actively raising more investments. The company is located in Ithaca, NY.